Vinuthana Pharma Tech Profile
Key Indicators
- Authorised Capital ₹ 9.00 Cr
as on 06-11-2024
- Paid Up Capital ₹ 9.00 Cr
as on 06-11-2024
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 21.13 Cr
as on 06-11-2024
- Revenue %
(FY 2023)
- Ebitda
- Net Worth
- Total Assets 32.34%
(FY 2023)
About Vinuthana Pharma Tech
The Corporate was formerly known as Preetham Life Sciences Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.00 Cr and a paid-up capital of Rs 9.00 Cr.
The company currently has active open charges totaling ₹21.13 Cr.
Venkata Kurre and Vasundhara Kurre serve as directors at the Company.
- CIN/LLPIN
U24290TG2020PTC144769
- Company No.
144769
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Oct 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Vinuthana Pharma Tech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Kurre  | Director | 12-Oct-2020 | Current |
| Vasundhara Kurre | Director | 01-Nov-2022 | Current |
Financial Performance of Vinuthana Pharma Tech.
Vinuthana Pharma Tech Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Vinuthana Pharma Tech?
In 2023, Vinuthana Pharma Tech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vinuthana Chem Tech Private LimitedActive 16 years 10 monthsVenkata Kurre and Vasundhara Kurre are mutual person
- Inno Powersys Private LimitedActive 5 years 2 months
Venkata Kurre and Vasundhara Kurre are mutual person
Charges (Loans)
₹21.13 Cr
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 21.13 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Aug 2023 | Hdfc Bank Limited | ₹8.13 Cr | Open |
| 04 Aug 2023 | Hdfc Bank Limited | ₹13.00 Cr | Open |
How Many Employees Work at Vinuthana Pharma Tech?
Vinuthana Pharma Tech has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vinuthana Pharma Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vinuthana Pharma Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
